Feasibility and efficacy of diabetic retinopathy screening among youth with diabetes in a pediatric endocrinology clinic: a cross-sectional study

Jeffrey L. Tapley¹, Gerald McGwin Jr.², Ambika P. Ashraf³, Paul A. MacLennan⁴, Koula Callahan¹, Karen Searcey¹, C. Douglas Witherspoon¹, Jinan Saaddine⁵ and Cynthia Owsley¹*

Abstract

Background: We examined the feasibility and efficacy of using a non-mydriatic camera to screen for diabetic retinopathy (DR) among youth with type 1 or type 2 diabetes seen in a pediatric endocrinology clinic serving Alabama, the state that has the highest diabetes rate in the United States.

Methods: 236 youths with type 1 or type 2 diabetes were screened for DR using a non-mydriatic camera. Visual acuity was also assessed. A questionnaire asked parents about diabetes and eye care history.

Results: Mean duration since diabetes diagnosis was 5.5 years. 66 % reported receiving an eye examination within the previous year. 97.5 % had images that were gradable. DR was detected in 3.8 % of participants. 9.1 % were visually impaired.

Conclusions: Use of a non-mydriatic fundus camera is feasible and efficacious for DR screening in youth with diabetes. DR screening at routine endocrinology visits may be beneficial in managing youth with diabetes and preventing irreversible vision loss, particularly for those in regions where diabetes rates are high.

Keywords: Diabetes mellitus, Diabetes complications, Diabetic retinopathy, Pediatrics, Visual acuity

Background

Diabetes is a significant, worldwide burden that has dramatically increased in recent years with no evidence of the trend abating. Of particular concern is the rise in both type 1 and type 2 diabetes among youth which has increased by 21.1 % and 30.5 %, respectively, from 2001 to 2009 [1]. As these rates increase, the number of youth with diabetic-related complications will also increase. Among these complications is diabetic retinopathy (DR) and associated vision loss. DR is the leading cause of new cases of blindness among young adults in the United States [2].

It is established that the risk of DR increases with duration of diabetes [3–5]. Retinopathy may not produce apparent symptoms until visual loss develops. Thus, early detection and treatment is important in reducing rates of diabetes related vision problems [6, 7]. However, findings from the SEARCH for Diabetes in Youth study showed that only two-thirds of those under age 18 years with type 1 and type 2 diabetes receive an annual comprehensive dilated eye exam, making it the least commonly followed of the American Diabetes Association (ADA) guidelines for diabetes care in youth [8]. Youth with diabetes were also less likely to obtain annual eye exams than their adult counterparts [9]. Multiple factors may contribute to this low rate of dilated eye examination, such as cost, inconvenience of visiting an eye care provider, transportation challenges, or insufficient knowledge about the risk of DR.

For adults with diabetes, non-mydriatic fundus cameras have been implemented as screening tools for DR [10–12]. These cameras are non-invasive, painless,
require minimal time, and produce high-quality fundus images that reveal most clinically significant cases of DR. Those who screen positive can be recommended for a follow-up dilated comprehensive eye examination by an ophthalmologist or optometrist. However, this screening approach has not been widely implemented in youth with diabetes, and few studies have evaluated its feasibility and potential usefulness in pediatric screening for DR [13–15]. The primary objective of this study was to examine the feasibility and efficacy of non-mydriatic diabetic retinopathy screening in youth with type 1 or type 2 diabetes seeking regular diabetes care in a pediatric endocrinology clinic located in Alabama, the state in the US having the highest rate of diabetes [16].

Methods
This study was conducted at the Pediatric Endocrinology Clinic of the University of Alabama at Birmingham (UAB). This clinic largely serves the state of Alabama, as well as regions of eastern Mississippi and the Florida panhandle. The study population consisted of youth with a clinical diagnosis of either type 1 or type 2 diabetes, ages 8 to 18 years, who attended this clinic. Diabetes diagnosis and type were confirmed by endocrinologists at the clinic. Approval from the Institutional Review Board of UAB was obtained prior to the study’s initiation.

Those meeting the inclusion criteria were identified through the endocrinology clinic’s appointment schedule for the period of June to August 2013. Parents/guardians of eligible youth were mailed a letter describing the study two weeks prior to the youth’s appointment inviting participation at his/her next diabetes clinic visit. At that visit, a research assistant determined if the parent/guardian and youth were interested in participating. Participants were enrolled after obtaining informed consent from the parent/guardian and assent from the youth. A brief survey was administered to the parent/guardian obtaining information on the youth’s history of diabetes, eye care utilization, barriers to receiving eye care, and demographic information. Information was obtained from the medical record on HbA1c, urine microalbumin, and lipid profile (total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides).

Walk-in letter acuity was assessed for each eye using the TitmusV2 Vision Screener (Sperian Protection Optical, Inc., Chester, VA). Ocular imaging was performed by a trained research assistant using a non-mydriatic fundus camera with autofocus (Model AFC-230, Nidek Inc., Fremont, CA) in a dimly lit room. The youth was positioned in a forehead/chin rest in front of the camera in a seated position. Three images from each eye were taken: the anterior segment of the eye and two images of the fundus (macula centered view and optic nerve head view). If the images were blurry or the youth blinked, additional images were taken to achieve good image quality. Testing lasted about five minutes.

Within one week of screening, the images were reviewed and graded for DR by an ophthalmologist specializing in retinal/vitreal disease using the UK National Health System’s classification system for diabetic retinopathy (Table 1) [17]. The ophthalmologist also noted ocular findings other than DR. Screening results were made available to the endocrinologist, and a letter was generated and sent to the parent/guardian of each participant describing screening results and follow up recommendations. Recommendations were adapted from the American Academy of Ophthalmology’s guidelines for DR follow-up [18]. Participants who screened negative for DR (R0) were sent a letter that encouraged them to make appointments for dilated eye examinations on an annual basis. Participants who screened positive for background DR (R1) or photocoagulation (P) were sent a letter that encouraged follow-up with an eye care provider “in the next few months” for a dilated comprehensive eye exam. Participants with pre-proliferative (R2), proliferative (R3), or maculopathy (M) were sent a letter describing the need for urgent referral to an ophthalmologist. Those who screened positive for any DR (R1, R2, R3, or M) were additionally telephoned by the endocrinologist to describe the results and need for referral. Participants with any of the six images determined unclassifiable/ungradable due to image quality (U) were sent a letter encouraging to follow-up with a comprehensive dilated eye examination.

Statistical analysis
Participants were categorized into one of three mutually exclusive eye care utilization groups, i.e., ≤12 months, >12 months, and never, based on parent/guardian survey responses regarding their child’s most recent eye care visit. Information on HbA1c and lipid profile (total

| Grade | Description          | Recommendation                                      |
|-------|----------------------|-----------------------------------------------------|
| R0    | No diabetic retinopathy | Re-evaluate in twelve months with either eye care provider or photographic screening |
| R1    | Background DR         | Refer to eye care provider                          |
| R2    | Pre-proliferative DR  | Refer to ophthalmologist promptly                   |
| R3    | Proliferative DR      | Refer to ophthalmologist promptly                   |
| M     | Maculopathy           | Refer to ophthalmologist promptly                   |
| P     | Photocoagulation      | Refer to eye care provider                          |
| U     | Unclassifiable/Ungradable | Refer to eye care provider                        |
cholesterol, LDL-C, HDL-C, and triglycerides) was categorized based on gender and age specific norms. Specifically, HbA1c was high if ≥8.5 % (69 mmol/mol) for <6 years of age; ≥8.0 % (64 mmol/mol) for 6–12 years of age; ≥7.5 % (58 mmol/mol) for 13–19 years of age [2]. Lipids were stratified into percentile categories according to published standards [19]. Urine albumin results were classified as normal (<30 mg/L), microalbuminuria (30–299 mg/L), and macroalbuminuria (>300 mg/L) [20]. Eye care utilization categories were compared for significant differences using analysis of variance for continuous variables, and Chi-square tests and Fisher’s exact tests, for categorical variables.

Results
We identified 575 eligible youths through the appointment schedule and sent letters describing the study. Of these, 252 (44 %) youths were approached in the clinic and invited to participate. The remaining youth were not approached if they were already being seen by the endocrinologist/nurse or were “no-shows” for their appointments; thus, they were unavailable for recruitment. Of the 252 youths approached for participation, 236 (92.9 %) consented to screening. Mean age for participants was 14.1 ± 2.7 years and 135 (57.2 %) were female (Table 2). In terms of race, 67.0 % were white, 29.7 % African American, and the remaining were Hispanic, Native American, or Asian.

Among the study participants, 85.6 % had type 1 diabetes and 14.4 % had type 2 diabetes (Table 2). Mean age at diabetes diagnosis was 8.6 ± 3.9 years, and mean duration of diabetes was 5.5 ± 3.5 years. HbA1c level was “high” in terms of age in 71.6 % of participants. Cholesterol, LDL, HDL, and triglycerides levels were greater than the 75th percentile in 34.4 %, 22.5 %, 80.9 %, and 56.4 % of participants, respectively. Urine albumin was normal (<30 mg/L) in 90.3 % of participants.

66.1 % of participants reported receiving a dilated comprehensive eye examination within the past 12 months, 19.9 % had an examination more than 12 months ago, and 14.0 % had never received an examination (Table 2). Those who had never received an eye examination tended to be younger than those who did have one, although this was not statistically significant (p = 0.142). Those who had an eye examination in the past 12 months were more likely to be diagnosed with diabetes at a younger age (p = 0.053) and have a longer duration of diabetes (p = 0.001). All but one parent/guardian responded that they were capable of taking their child to an ophthalmologist or optometrist to receive a comprehensive dilated eye exam if necessary.

All participants were able to cooperate in sitting before the camera. Images from 6 participants (2.5 %) were determined unreadable (a single eye for 2 and both eyes for 4). All unreadable images were due to the youth’s inability to keep their eyes open during the photographic flash. Mean age for participants with unreadable images was 14.4 years, which was not different than the mean age of participants with readable images (p = 0.733).

Nine participants (3.9 %) had DR in at least one eye, the majority of which was background DR (Table 3). One participant with background DR showed signs of maculopathy, and one participant displayed evidence of previous photocoagulation treatment. Ten participants (4.3 %) had other types of ocular findings detected in at least one eye. These included venous loop, media opacities, choroidal coloboma, white centered hemorrhage, pale/abnormal disc, increased cup/disc ratio, and atrophic macular scar. Having any DR (n = 9) was associated with duration of diabetes (mean duration 7.8 ± 3.7 years with retinopathy versus 5.4 ± 3.5 years without retinopathy, p = 0.046). There were no associations between DR presence and other variables, including age at diagnosis, diabetes type and clinical laboratory values.

A sensitivity analysis restricting the study group to those who met ADA guidelines for recommended dilated comprehensive eye examination was performed (i.e., for type 1, a dilated comprehensive eye examination is recommended at the start of puberty or at age ≥10 years, whichever is earlier, once the child has had diabetes for 3–5 years, with annual follow-up thereafter; for type 2, a dilated eye examination is recommended at diagnosis, and then annually thereafter) [2]. This analysis included 140/202 (69.3 %) of participants with type 1 diabetes and all 34 participants with type 2 diabetes. Of the 174 participants who met ADA criteria for dilated examination, two subjects had unclassifiable/ungradable images for both eyes. Among the 172 participants with readable images, eight (4.7 %) subjects had DR in at least one eye, i.e., six (3.5 %) had background DR and two (1.2 %) had proliferative DR.

Overall, 115 participants (49.8 %) had corrective lenses (either glasses or contact lenses); of these, 54 participants (23.4 %) did not bring their corrective lenses to the appointment. Acuity was measured in all participants, even if they did not have their corrective lenses. Table 4 provides acuity screening results for the better and worse seeing eyes; 24.2 % of participants had 20/20 acuity in both eyes; 58.4 % of participants had worse than 20/20 acuity in the better seeing eye, and 75.8 % had worse than 20/20 in the worse seeing eye. 19.5 % of participants met the criteria for visual impairment, defined as 20/40 or worse in the better seeing eye.

Because almost one fourth of the sample had corrective lenses but did not bring them, results could be influenced by a refractive error that is normally corrected. When Table 4 excluded participants who did not bring their lenses, only 29.4 % had 20/20 acuity in both
eyes. After excluding participants who did not bring their glasses, acuity worse than 20/20 was associated with a younger age ($p = 0.042$), a shorter duration of diabetes ($p = 0.030$), and type 2 diabetes ($p = 0.015$); 32.3% of participants with type 1 diabetes and 5.3% with type 2 diabetes had 20/20 acuity in both eyes. Visual acuity did not differ with regard to gender, race/ethnicity, recency of last dilated eye exam, age at diabetes diagnosis, or presence of DR.

**Discussion**
Our results suggest that non-mydriatic fundus imaging among youth with diabetes conducted at a routine endocrinology appointment is a feasible way to screen for DR. Almost all parents/guardians who were approached agreed to have their son or daughter screened, and over 97% of participants had images that were gradable, a rate that is comparable to other pediatric DR screening studies using a non-mydriatic camera [13, 14].

### Table 2
Demographic, clinical, and laboratory characteristics of participants by recency of dilated eye examination

|                    | Total (N = 236) | Eye exam ≤ 12 months (N = 156) | Eye exam > 12 months (N = 47) | Never (N = 33) | P-value |
|--------------------|----------------|--------------------------------|-------------------------------|---------------|---------|
| **Demographics**   |                |                                |                               |               |         |
| Age, years, mean (standard deviation, SD) | 14.1 (2.69) | 14.1 (2.58) | 14.9 (2.7) | 12.8 (2.8) | 0.142   |
| Minimum - maximum  | 8.0-18.9       | 8.0-18.9                       | 9.4-18.9                      | 8.3-18.4      |         |
| Gender, N (%)      |                |                                |                               |               |         |
| Male               | 101 (42.8)    | 68 (43.6)                      | 22 (46.8)                     | 11 (33.3)    | 0.459   |
| Female             | 135 (57.2)    | 88 (56.4)                      | 25 (53.2)                     | 22 (66.7)    |         |
| Race, N (%)        |                |                                |                               |               |         |
| White, non-Hispanic origin | 158 (67.0) | 109 (69.9) | 25 (59.6) | 21 (63.6) | 0.225   |
| African American   | 70 (29.7)     | 43 (27.6)                      | 17 (36.2)                     | 10 (30.3)    |         |
| Hispanic           | 5 (2.1)       | 3 (1.9)                        | 0 (0)                         | 2 (6.1)      |         |
| Native American    | 2 (0.9)       | 1 (0.6)                        | 1 (2.1)                       | 0 (0)        |         |
| Asian              | 1 (0.4)       | 0 (0)                          | 1 (2.1)                       | 0 (0)        |         |
| **Clinical characteristics** |          |                                |                               |               |         |
| Type, n (%)        |                |                                |                               |               | 0.824   |
| Type 1             | 202 (85.6)    | 135 (86.6)                     | 39 (83.0)                     | 28 (84.8)    |         |
| Type 2             | 34 (14.4)     | 21 (13.5)                      | 8 (17.0)                      | 5 (16.0)     |         |
| Age at diabetes diagnosis, years, mean (SD) | 8.6 (3.9) | 8.2 (4.0) | 9.6 (4.0) | 9.2 (3.5) | 0.053   |
| Duration of diabetes diagnosis, years, mean (SD) | 5.5 (3.5) | 5.9 (3.4) | 5.4 (4.0) | 3.6 (2.5) | 0.001   |
| **Laboratory characteristics** |          |                                |                               |               |         |
| HbA1c high for age*, n (%) | 169 (71.6) | 115 (73.7) | 32 (68.1) | 22 (66.7) | 0.599   |
| Cholesterolb, n (%) |                |                                |                               |               |         |
| >75th percentile   | 86 (34.4)     | 51 (32.7)                      | 26 (55.3)                     | 9 (27.3)     | 0.009   |
| LDLc, n (%)        |                |                                |                               |               |         |
| >75th percentile   | 53 (22.5)     | 33 (21.2)                      | 16 (34.0)                     | 4 (12.1)     | 0.055   |
| HDLc, n (%)        |                |                                |                               |               |         |
| >75th percentile   | 191 (80.9)    | 122 (78.2)                     | 44 (93.6)                     | 25 (75.8)    | 0.046   |
| Triglyceridesd, n (%) |            |                                |                               |               |         |
| >75th percentile   | 133 (56.4)    | 85 (54.5)                      | 33 (70.2)                     | 15 (45.5)    | 0.064   |
| Urine Albumin*, n (%) |                |                                |                               |               | 0.963   |
| Normal (<30 mg/L)  | 213 (90.3)    | 141 (90.4)                     | 42 (89.4)                     | 30 (90.9)    |         |
| Microalbuminuria (30–299 mg/L) | 22 (9.3)  | 14 (9.0)                      | 5 (10.6)                      | 3 (9.1)      |         |
| Macroalbuminuria (≥300 mg/L) | 1 (0.4)   | 1 (0.6)                       | 0 (0)                         | 0 (0)        |         |

*aHbA1c is high if ≥ 8.5% (69 mmol/mol) for < 6 years of age; ≥ 8.0% (64 mmol/mol) for 6 – 12 years of age; ≥ 7.5% (58 mmol/mol) for 13 – 19 years of age [2]
*bPercentile categories are based from Gender and Age specific norms [19]
*cUrine albumin was reported in mg/L; normal was < 30 mg/L, microalbuminuria was defined as ≥ 30 and < 300 mg/L, and macroalbuminuria was defined as ≥ 300 mg/L [20]
rates of readable images are considerably higher than adult rates [21, 22], which may stem from the larger pupil size typical of youth. Increasing age is the strongest predictor of ungradable image rates for non-mydriatic imaging [23]. Good imaging quality was just as likely in younger versus older youth. The average time for screening was brief, considerably less time than required for a dilated eye examination. The brevity of the screening process and the reduced burden of not dilating the pupil may facilitate increasing the number of youth screened for DR.

A small percentage of youth screened positive for DR (~4 %), not surprising since pediatric populations typically have a briefer duration of diabetes compared to adults, which decreases the risk for DR [3–5]. Given that 33 % of participants in this study had not received a dilated eye examination in the past year or never had one, the endocrinologist office screening represented a convenient opportunity to assess retinal health. The vast majority of DR detected was background DR (7 of 9 cases), which suggests high potential for intervention in DR’s earliest phases when treatment can prevent vision loss [2].

Only 66 % of participants received a dilated eye exam within the previous 12 months, which agrees with the rate reported in the SEARCH for Diabetes in Youth study [8, 9]. Even lower rates have been reported in studies based in Philadelphia (64 %) and Ohio (53.5 %) [24, 25]. Low rates of annual eye care utilization is concerning since early DR detection and treatment reduce the risk of irreversible vision loss [2]. Our results indicate that youth with a longer duration of diabetes were more likely to receive an eye exam within the past year, agreeing with a recent study [14]. Although this trend is desirable, it is still apparent that many youth with diabetes underutilize eye care services.

All but one parent/guardian in our study stated they were capable of taking their child to an eye care provider to receive a comprehensive eye care if necessary, and did not cite barriers to care. This suggests that efforts to improve dilated eye examination rates should focus on educating parents/guardians about the importance of routine eye care for youth with diabetes. Another potential mechanism underlying low dilated examination rates among youth with diabetes may be that pediatricians and/or endocrinologists are not effectively communicating the importance of annual dilated eye care during routine patient check-ups. Research has shown that adults with diabetes are more compliant to vision guidelines when screening is routinely recommended by their physician [26]. However, research on teenagers found that only 35 % of teenagers with diabetes were referred by their endocrinologist to eye care providers for annual examinations [27]. Thus, it appears that pediatricians, other primary care physicians, and endocrinologists could be more vigilant in recommending annual dilated eye examinations for their patients with diabetes.

One important aspect of any screening program is its potential to reduce health care costs, including the financial burden of untreated disease [28]. There is growing evidence that non-mydriatic cameras are a cost-effective screening tool for DR in adults with diabetes [29]; however, there has been little research on the cost-effectiveness of DR screening tools for youth with diabetes. Huo et al. [30] found that implementing ADA recommendations for annual dilated exams were not cost effective for youth with type 1 diabetes who had excellent glycemic control, given the low rates of retinopathy actually present in these patients. Non-mydriatic cameras in the endocrinology office may be a cost-effective alternative tool for pediatric DR detection.

Most studies show a direct correlation between duration of disease and development of DR, with retinopathy occurring after at least 3 years since diagnosis and

---

**Table 3** Descriptive characteristics of participants with diabetic eye disease

| Finding                          | Total (N = 232)* (%) |
|---------------------------------|----------------------|
| Total diabetic eye disease      | 9 (3.9)              |
| (including DR and maculopathy)  |                      |
| Background DR                   | 7 (3.0)              |
| Pre-proliferative DR            | 0 (0)                |
| Proliferative DR                | 2 (0.9)              |
| Maculopathy                     | 1 (0.4)              |
| Other lesions                   | 10 (4.3)             |

*Four subjects were unclassifiable/ungradable for both eyes

---

**Table 4** Visual acuity among study participants

| Visual acuity score  | Total sample (N = 231)* (%) | Omitting those who had glasses but did not bring them to appointment (N = 177)* (%) |
|----------------------|-------------------------------|---------------------------------------------------------------------------------|
| Better eye acuity    |                               |                                                                                |
| 20/20                | 96 (41.6)                     | 88 (49.7)                                                                       |
| 20/30                | 90 (39.0)                     | 73 (41.2)                                                                       |
| 20/40                | 29 (12.6)                     | 10 (5.7)                                                                        |
| 20/50                | 13 (5.6)                      | 5 (2.8)                                                                         |
| 20/70                | 3 (1.3)                       | 1 (0.6)                                                                         |
| Worse eye acuity     |                               |                                                                                |
| 20/20                | 56 (24.2)                     | 52 (29.4)                                                                       |
| 20/30                | 92 (39.8)                     | 81 (45.8)                                                                       |
| 20/40                | 38 (16.5)                     | 26 (14.7)                                                                       |
| 20/50                | 26 (11.5)                     | 10 (5.7)                                                                        |
| 20/70                | 11 (4.8)                      | 5 (2.8)                                                                         |
| 20/100               | 8 (3.5)                       | 3 (1.7)                                                                         |

*Five participants were unable to perform visual acuity test
In this study, we report a mean duration of 7.8 years for those with retinopathy compared to 5.4 years without retinopathy ($p = 0.0461$). Interestingly, we identified two cases of background retinopathy present after only 2 years since diagnosis – one case each in both a type 1 and type 2 youth with diabetes. Other studies have also reported early retinopathy in youth with less than three years duration [32, 33]. This is notable, considering current ADA guidelines for type 1 diabetes recommend screening to begin for those ≥10 years old having diabetes for 3–5 years [2]. With regard to clinical characteristics, our study did not identify any significant risk factors associated with retinopathy other than duration of diabetes. Further studies are needed to better identify clinical variables and their associations with DR in order to provide more effective and targeted screening in youth with diabetes [34].

There has been little research on vision impairment among youth with diabetes. In our study, almost half (49.8 %) of the sample used corrective lenses. However, only 47 % of those with corrective lenses wore them to their regular endocrinologist appointment at the time of screening, suggesting that some youth with diabetes are not wearing corrective lenses routinely even though they have been prescribed. Further exploration may provide insights into reasons for spectacle noncompliance in youth with diabetes. Walk-in visual acuity for many youth in our sample was markedly low. Even after excluding those who did not bring their corrective lenses to the screening, 9.1 % of participants met the criteria for visual impairment and only 29.4 % had 20/20 vision in both eyes. As most parents/guardians of youth with diabetes understand the importance of routine visits to the endocrinologist and/or pediatrician, there appears to be room for improved education on the importance of vision care.

Strengths and limitations of this study should be noted. To our knowledge, this is the only study that has examined the feasibility of DR screening in youth using a non-mydriatic camera during routine pediatric endocrinology clinic visits. The pediatric endocrinology clinic serving as the study setting is in Alabama, which has the highest rate of diabetes in the US [16]. Although the study was unable to enroll all youth scheduled for an appointment during the study period, nearly all parents/guardians who were invited consented to participate. A limitation was the self-reported diabetes history and vision care utilization obtained from our survey, rather than extracting this information from medical records. The extent to which participants who screened positive for DR or other ocular findings pursued follow-up examinations with an ophthalmologist or optometrist was not part of the study’s scope, but this issue will be addressed in future work. Future work should also compare the non-mydriatic photography method used in this study to the clinical gold-standard dilated eye examination.

**Conclusion**

We have shown that a non-mydriatic fundus camera is a feasible and efficacious method to screen for diabetic retinopathy in youth with diabetes in a region of the US that has the highest rate of diabetes in the nation. With approximately 1/3 of youth with diabetes not receiving annual, dilated eye exams, screening programs implemented during a routine endocrinologist appointment may be beneficial in the management of youth with diabetes and prevention of irreversible vision loss, particularly in those regions of the US with high diabetes rates.

**Abbreviations**

ADA: American diabetes association; DR: Diabetic retinopathy; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; UAB: University of Alabama at Birmingham.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

JLT, GM, APA, PAM, KS, CDW, and CO designed the study. JLT, GM, APA, PAM, KS, CDW, JS, and CO interpreted the data. JLT, KS, KC, and CDW collected and managed the data. GM, PAM, and KS performed the statistical analysis of the data. All authors participated in drafting the manuscript and read and approved of the final manuscript.

**Acknowledgments**

Funding was provided by Centers for Disease Control and Prevention (CDC) Cooperative Agreement #5U58DP002651 with the University of Alabama at Birmingham. Supplemental funding was provided by Research to Prevent Blindness, the EyeSight Foundation of Alabama, and the Buck Trust. Research to Prevent Blindness, the EyeSight Foundation of Alabama, and the Buck Trust had no role in the design, collection, analysis, and interpretation of the data, in writing the manuscript, and the decision to submit the manuscript for publication. A medical epidemiologist at CDC (JS) participated in the interpretation of the data and writing the manuscript since this study was funded by a cooperative (and thus collaborative) agreement with CDC.

**Disclaimer**

The findings and conclusions in this paper are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention.

**Author details**

1. Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
2. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
3. Department of Pediatrics/Division of Endocrinology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
4. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
5. Vision Health Initiative, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.

Received: 26 March 2015 Accepted: 17 June 2015

Published online: 24 June 2015

**References**

1. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001–2009. JAMA. 2014;311:1778–86.

2. American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care. 2014;37 Suppl 1: S14–80.
3. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520–6.

4. Fong DS, Akelel LM, Gardner TW, King GI, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(Suppl 5):S84–57.

5. Raczynska D, Zorena K, Urban B, Zaleski D, Sorek A, Maukiewicz G, et al. Current trends in the monitoring and treatment of diabetic retinopathy in young adults. Mediators Inflamm. 2014;2014:92926.

6. Early Treatment Diabetic Retinopathy Study Research Group. Early photoacoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(Suppl):766–85.

7. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: diabetic retinopathy vitrectomy study report S. Arch Ophthalmol. 1990;108:958–64.

8. Hamman RF, Bell RA, Dabelea D, D’Agostino RBl, Dolan L, Imperatore G, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014;37:3336–44.

9. Waintzfelder B, Phihoker C, Klingensmith G, Case D, Anderson AJ, Bell RA, et al. Adherence to guidelines for youths with diabetes mellitus. Pediatrics. 2012;128:531–8.

10. Lin DY, Blumenkrantz MS, Brothers RJ, Groversen OM. The sensitivity and specificity of single-field monomdriftic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol. 2002;134:204–13.

11. Massin P, Erginay A, Mehidi AB, Vicaire E, Quintel G, Victor Z, et al. Evaluation of a new non-mydriatic digital camera for detection of diabetic retinopathy. Diabet Med. 2003;20:635–41.

12. Bragge P, Gruen RL, Chau M, Forbes A, Taylor HR. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol. 2011;129:435–44.

13. Stillman JK, Goe GA, Wootton R, Woolfield N, Price D, Van der Westhuuven J, et al. Tele paediatrics and diabetic retinopathy screening of young people with diabetes in Queensland. J Telemed Telecare. 2004;10(Suppl):92–4.

14. Kolomeyer AM, Nayak NV, Simon MA, Szirth BC, Shahid K, Sheng IY, et al. Feasibility of retinal screening in a pediatric population with type 1 diabetes. J AAPOS. 2014;18:299–306.

15. Minuto N, Emmanuelle V, Vannati M, Russo C, Rebosa C, Panarrello S, et al. Retinopathy screening in patients with type 1 diabetes diagnosed in young age using non-mydriatic digital stereoscopic retinal imaging. J Endocrinol Invest. 2012;35:899–904.

16. Alabama Department of Public Health. Diabetes in Alabama. Alabama Department of Public Health, Montgomery, AL. 2010. https://adph.org/diabetes/assets/DiabetesinALReport03.pdf. Accessed 23 Mar 2015.

17. Harding SP, Greenwood R, Addington S, Gibson J, Owens DA, Taylor R, et al. Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med. 2003;20:965–71.

18. American Academy of Ophthalmology Preferred Practice Patterns Committee. Preferred Practice Pattern Guidelines: Comprehensive Adult Medical Eye Evaluation 2010. American Academy of Ophthalmology, San Francisco CA. http://www.aao.org/preferred-practice-pattern/comprehensive-adult-medical-eye-evaluation-octobe. Accessed 23 June 2015.

19. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:108–208.

20. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011;34:e61–99.

21. Peters A, Davidson WB, Ziel FH. Cost-effective screening for diabetic retinopathy using a nonmydriatic retinal camera in a prepaid health-care setting. Diabetes Care. 1993;16:1193–5.

22. Scanlon PH, Malhotra R, Thomas G, Foy C, Kirkpatrick JN, Lewis-Garne N, et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabet Med. 2002;19:657–74.

23. Scanlon PH, Foy C, Malhotra R, Aldingston SJ. The influence of age, duration of diabetes, cataract, and pupil size on image quality in digital photographic retinal screening. Diabetes Care. 2005;28:2448–53.

24. Valént D, Pestkal K, Otis M, Shubrook J. Type 2 diabetes in the pediatric population: are we meeting ADA clinical guidelines in Ohio. Clin Pediatr. 2010;49:316–22.

25. Dumsen SM, Ratcliffe SJ, Langdon DR, Murphy KM, Lipman TH. Racial disparities in screening for diabetic retinopathy in youth with type 1 diabetes. Diabetes Res Clin Pract. 2013;10:13–5.

26. Schonfeldt ER, Greene JM, Wu SY, Leske C. Patterns of adherence to diabetes vision care guidelines. Ophthalmology. 2001;108:563–71.

27. Rosenberg JB, Friedman IB, Gurland JE. Compliance with screening guidelines for diabetic retinopathy in a large academic children’s hospital in the Bronx. J Diabetes Complications. 2011;25:222–6.

28. Scanlon PH. The English National Screening Programme for sight threatening retinopathy. J Med Screen. 2008;15:1–4.

29. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med. 2010;27:249–56.

30. Hsu B, Steffen AT, Swan K, Skiles K, Wenzlumer SA, Tamborlane W. Clinical outcomes and cost-effectiveness of retinopathy screening in youth with type 1 diabetes. Diabetes Care. 2007;30:362–3.

31. Lueder GT, Silverstein J. Screening for retinopathy in the pediatric patient with type 1 diabetes mellitus. Pediatrics. 2005;116:270–3.

32. Donaghue KC, Fairchild JM, Chan A, Hing SJ, King J, Howard NJ, et al. Diabetes microvascular complications in prepubertal children. J Pediatr Endocrinol Metab. 1997;10:579–85.

33. Holl RW, Lang A, Grabent M, Heinze E, Lang GK, Debakin TM. Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. Pediatr. 1998;132:790–4.

34. Forlenza GP, Stewart MW. Diabetic retinopathy in children. Pediatr Endocrinol Rev. 2012;10:217–26.